Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
by on Thursday, October 13th, 2011 | No Comments
Conditions: Myelodysplastic Syndrome; Acute Myeloid Leukemia
Interventions: Drug: Panobinostat; Drug: Panobinostat
Sponsor: Johann Wolfgang Goethe University Hospitals
Recruiting – verified October 2011